Biotherapeutics Launches a New Fundraising Campaign at BIO’2015
BLACKSBURG, VA: June 18, 2015 - The Biotherapeutics (BTI) team traveled to Philadelphia June 16-19 to launch a new fundraising campaign that will allow the Company to complete IND-enabling TOX package, and initiate human clinical trials.
“BTI’s clinical candidate for Crohn’s disease (CD) is supported by data packages with strong animal pharmacology, validated MOA, promising safety profile, and impressive human translational data.” Said Dr. Carbo, Scientific Director.
“We are seeking $20M in Series A funding to complete IND-enabling toxicology studies, and initiate human clinical trials by 2016 and Phase IIa studies in the second half of 2017.” Said Dr. Bassaganya-Riera, President and CEO.
The BTI team will also attend the JP Morgan Healthcare Conference in January of 2016 to continue advancing its expansible drug discovery and development pipeline.
About Biotherapeutics Inc.
Biotherapeutics Inc. is a science-based biotech company dedicated to developing disruptive oral, small molecule therapeutics for inflammatory diseases and diabetes. BTI’s scientific foundation is anchored on informatics and computer modeling-enabled drug development with significant animal pharmacology validation. Through focused execution, innovative proprietary technology with strong IP, and committed leadership, BTI intends to advance its expansible product pipeline into clinical development with a significant market opportunity.